Acamprosate (Campral) Medication for Alcohol Abuse & Addiction

Last Updated: May 15, 2024

Editorial Policy | Research Policy

Key Takeaways

  • Alcohol Use Disorder (AUD) affects approximately 11% of the U.S. population, with under 15% receiving treatment.
  • Acamprosate, approved by the FDA in 2004, helps maintain abstinence from alcohol but does not treat withdrawal symptoms.
  • The medication works by stabilizing brain chemistry, particularly affecting GABA and glutamate neurotransmitters.
  • Over 25 clinical trials have shown Acamprosate to be more effective than placebo in reducing drinking and promoting abstinence.
  • Clinical trials and studies are crucial for understanding Acamprosate’s efficacy and safety, with ongoing research to optimize treatment.
  • Common side effects of Acamprosate include gastrointestinal issues, with serious risks like suicidal thoughts being less common.
  • Acamprosate is often compared with other AUD treatments like naltrexone and disulfiram, each having unique mechanisms and side effects.
  • Patient experiences with Acamprosate vary, with many finding it beneficial when combined with psychosocial support.
  • Future research in Acamprosate aims to personalize AUD treatment and improve understanding of its mechanisms.

Alcohol Use Disorder: Prevalence and Impact

Alcohol Use Disorder (AUD) is a significant public health concern characterized by an unhealthy pattern of alcohol consumption that leads to distress or impairment. The current prevalence of AUD in the U.S. is approximately 11%, signifying a widespread issue affecting millions. Despite its high prevalence, under 15% of individuals with a lifetime diagnosis of AUD receive treatment. The disorder’s etiology is complex, with nearly equal contributions from genetic and environmental factors, underscoring the importance of a multifaceted approach to treatment and prevention.

According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), AUD is diagnosed based on the presence of two or more specific criteria within a 12-month period. Severity is classified as mild, moderate, or severe based on the number of criteria met. The impact of AUD is far-reaching, affecting individuals’ physical health, mental well-being, and social relationships, while also contributing to societal issues such as increased healthcare costs, lost productivity, and social disruptions.

Alarmingly, data indicates that certain U.S. states, such as Oklahoma, Oregon, New Mexico, Utah, and Mississippi, exhibit notably high rates of alcohol-related deaths. This geographic variability highlights the need for targeted interventions and policies. The World Health Organization (WHO) emphasizes cost-effective interventions to reduce harmful alcohol use and promotes the dissemination of scientific information on alcohol use and dependence. Meanwhile, the National Institute on Alcohol Abuse and Alcoholism (NIAAA) provides resources to educate and inform the public and healthcare professionals about AUD, its treatment, and the importance of early intervention.

Despite available evidence-based treatments, including FDA-approved medications like acamprosate, disulfiram, and naltrexone, the under-treatment of AUD remains a critical challenge in healthcare. This underscores the necessity for enhanced screening, awareness, and accessibility to treatment options for those struggling with AUD.

Introduction to Acamprosate in Alcohol Use Disorder Treatment

Acamprosate, commercially known as Campral, is a medication prescribed for the treatment of Alcohol Use Disorder (AUD). Having gained approval from the U.S. Food and Drug Administration in 2004, acamprosate is recognized for its efficacy in helping individuals maintain abstinence from alcohol. The medication is often used as part of a comprehensive treatment program that includes counseling and social support. It’s important to note that acamprosate does not treat the symptoms of alcohol withdrawal but rather works to stabilize chemical imbalances in the brain caused by long-term alcohol consumption.

The chemical composition of acamprosate is thought to be effective due to its similarity to gamma-aminobutyric acid (GABA), a neurotransmitter in the brain that produces calming effects. By modulating the activity of both excitatory and inhibitory neurotransmitters altered by prolonged alcohol intake, acamprosate helps to reduce the cravings and urge to drink, thus assisting individuals in their recovery journey. It typically comes in a time-release tablet form and is taken multiple times a day, with the dosing regimen often lasting up to 12 months to support long-term sobriety.

As with any medication, it is crucial that acamprosate is taken under the guidance of healthcare professionals, starting post-withdrawal and continuing even in the event of a relapse, according to treatment protocols. This approach ensures that the medication contributes to the holistic management of AUD, enabling individuals to regain control over their drinking habits.

How Acamprosate Works to Combat Alcohol Use Disorder

Acamprosate, a medication prescribed for the treatment of Alcohol Use Disorder (AUD), functions by restoring the delicate balance between the brain’s excitatory and inhibitory neurotransmitters. The exact mechanism of action remains under scrutiny, but current research suggests that Acamprosate primarily acts by modulating neurotransmitter systems to reduce the neurological distress associated with alcohol withdrawal.

By affecting neurotransmitters such as glutamate and gamma-aminobutyric acid (GABA), the drug appears to decrease hyperexcitability that often results from prolonged alcohol exposure. Studies indicate that Acamprosate works by promoting a balance between these neurotransmitters, potentially reducing the craving and relapse rates in individuals with AUD.

Furthermore, Acamprosate may interact with neuronal NMDA receptors and calcium channels, which are believed to be implicated in the development of alcohol dependence. The medication’s influence on N-methyl-D-aspartic acid (NMDA) receptor transmission and its indirect effects on GABA type A receptor transmission could explain its efficacy in diminishing reinstatement in ethanolized rodents and promoting abstinence in humans, as outlined in clinical pharmacology studies.

While the drug’s precise action is yet to be fully understood, the therapeutic benefits of Acamprosate in managing AUD are supported by its ability to decrease brain glutamate levels and increase β-endorphins, offering a promising avenue for those seeking to maintain sobriety.

Acamprosate’s Role in Managing Alcohol Use Disorder

Acamprosate, a medication prescribed for Alcohol Use Disorder (AUD), has been the subject of extensive research, revealing its significant role in promoting abstinence and reducing the risk of relapse in individuals with alcohol dependence. With evidence from over 25 placebo-controlled, double-blind trials, acamprosate has generally been found to be more efficacious than placebo in reducing the risk of return to any drinking and increasing the cumulative duration of abstinence. Studies have shown that the risk of returning to drinking while on acamprosate is 14 percent less than for those treated with a placebo.

Despite mixed evidence from U.S. studies, European trials consistently support the efficacy of acamprosate, demonstrating its ability to reduce drinking days, increase complete abstinence rates, and extend the time to relapse. As an amino acid modulator, acamprosate is thought to reduce craving and has also been associated with improved treatment retention. It is generally well-tolerated by patients, making it a viable option for long-term treatment. The American Family Physician notes that acamprosate’s effectiveness is further supported by the ‘number needed to treat to prevent one person from returning to any drinking,’ which is estimated to be 11.

Overall, acamprosate is indicated for maintaining abstinence from alcohol in patients with AUD, with the potential to significantly contribute to the management of this disorder. However, as with any medication, its effectiveness can vary among individuals, and it may present limitations that need to be considered in the context of comprehensive treatment planning.

Exploring Clinical Trials and Studies on Acamprosate for Alcohol Use Disorder

Clinical trials and studies have been instrumental in understanding the efficacy and safety of Acamprosate, a medication indicated for the treatment of Alcohol Use Disorder (AUD). Acamprosate, chemically known as calcium acetylhomotaurine, acts as an amino acid modulator and has been approved by the FDA for this purpose. Its mechanism, thought to restore the balance between excitatory and inhibitory neurotransmitters, has shown promise in promoting abstinence and reducing cravings post-detoxification.

A systematic review including data from 118 clinical trials with over 20,000 participants has highlighted that Acamprosate may be effective in preventing relapse. The number needed to treat (NNT) to prevent one person from returning to any drinking was found to be 11, which indicates a favorable outcome for Acamprosate compared to other treatments like oral naltrexone.

Furthermore, the safety profile of Acamprosate is under continuous evaluation, particularly in individuals with alcohol-related liver disease. Several interventional trials aiming to assess the safety of long-term use of Acamprosate in this subset of patients. Adherence to treatment and the effectiveness of Acamprosate are also areas of ongoing research, with studies employing various methodologies to ensure the reliability of reported rates of adherence.

The pursuit of genetic and metabolomic biomarkers to predict sobriety or relapse in individuals receiving Acamprosate is another avenue being explored, which could potentially personalize AUD treatment. The comprehensive data available from these trials and studies continue to inform clinicians and shape the future of AUD treatment strategies.

Side Effects and Risks Associated with Acamprosate

Acamprosate, a medication utilized in the treatment of Alcohol Use Disorder (AUD), is known for its capacity to help maintain abstinence from alcohol in patients who have ceased drinking. While it is a critical component of a holistic treatment plan that includes psychosocial support, it is essential for patients and healthcare providers to be aware of the potential side effects and risks associated with its use.

  • Common side effects of Acamprosate include gastrointestinal disturbances such as diarrhea, nausea, vomiting, gas, and stomach pain, as well as loss of appetite, headache, drowsiness, and dizziness.
  • Patients may also experience constipation, tiredness, weight fluctuations, muscle or joint pain, and changes in sexual desire.
  • A serious potential side effect is the emergence of suicidal thoughts or behaviors, particularly for individuals with a history of depression.
  • Other adverse reactions can include signs of an allergic reaction, such as rash, hives, and difficulty breathing.
  • For those with severe kidney disease, Acamprosate is not recommended due to the risk of serious side effects.
  • In cases of overdose, symptoms may include abdominal pain, confusion, dry mouth, incoherent speech, and increased urination.

It is vital for individuals considering or currently taking Acamprosate to communicate openly with their healthcare providers about any side effects experienced and to have a clear understanding of the potential risks involved. This ensures that any adverse effects are managed promptly and effectively, contributing to the overall success of the treatment plan for AUD.

We offer physician-led treatment for drug and alcohol addiction in New Jersey. Call us today to speak with a Recovery Advocate for free about your treatment options.

Comparing Acamprosate to Other Alcohol Use Disorder Treatments

Acamprosate, known chemically as calcium acetylhomotaurine, is a medication used to treat Alcohol Use Disorder (AUD) by reducing cravings and promoting abstinence post-detoxification. It is often considered safe and generally well-tolerated, but its clinical efficacy varies across different studies. In terms of mechanism, Acamprosate modulates amino acid activity and helps maintain a balance between excitatory and inhibitory neurotransmitters in the brain, which is crucial for individuals recovering from alcohol dependence.

When compared to other treatment options like naltrexone and disulfiram, Acamprosate presents a different side effect profile and method of action. Naltrexone, which also assists in reducing cravings for alcohol, works by blocking opioid receptors, while Disulfiram acts as a deterrent by causing unpleasant physical reactions when alcohol is consumed. Clinical trials suggest that the combination of Acamprosate with other medications, such as naltrexone, may enhance treatment efficacy. However, individual responses can vary, and the best treatment approach often requires personalized assessment.

Comparative studies and meta-analyses have shown that while Acamprosate’s effects are modest, they are clinically significant and contribute to the multifaceted approach required to treat AUD. It is critical to consider not only the direct effects of these medications but also their potential to be integrated into broader treatment plans that include psychosocial support and lifestyle adjustments. The choice between Acamprosate and other treatments depends on various factors, including individual patient characteristics, side effect tolerance, and the specific objectives of the treatment plan.

The efficacy of Acamprosate relative to other treatments is an ongoing area of research, as scientists and clinicians strive to optimize therapy for AUD. Future developments may reveal more about how Acamprosate can be best utilized in the context of comprehensive treatment strategies.

Comparing Acamprosate and Naltrexone in Alcohol Use Disorder Treatment

Both Acamprosate and Naltrexone are FDA-approved medications critical in the treatment of Alcohol Use Disorder (AUD), each with distinct mechanisms of action and effectiveness profiles. Acamprosate, known chemically as N-acetyl homotaurine, operates as an NMDA receptor modulator and is believed to restore the balance between excitatory and inhibitory neurotransmitters, glutamate and GABA, thus reducing the craving for alcohol. It is typically prescribed in tablet form and taken three times daily.

Naltrexone, on the other hand, is a broad-spectrum opioid receptor antagonist, which primarily binds to the μ-opioid receptor subtype. This action helps diminish the reinforcing effects of alcohol consumption by blocking the opioid receptors associated with the rewarding effects of drinking. It is available in both tablet form and as an intramuscular injection, known as Vivitrol.

A 2004 randomized controlled trial (RCT) indicated that both medications, alone or in combination, can prevent relapse in recently detoxified adults. However, some studies suggest that Acamprosate might be slightly more effective at helping individuals abstain from alcohol, while Naltrexone has also been used effectively in the treatment of opioid use disorder. It’s important to note that the choice between these medications may be influenced by patient-specific factors, including co-occurring conditions and personal response to treatment.

Understanding the side effects is also crucial. While Acamprosate is generally well-tolerated, potential side effects can include gastrointestinal disturbances and mood fluctuations. Naltrexone’s side effects may include nausea, headache, and dizziness, and it must be used with caution in individuals with liver dysfunction.

Ultimately, the decision on whether to use Acamprosate or Naltrexone should be made collaboratively between a healthcare provider and the patient, considering the unique aspects of the individual’s situation and medical history.

Comparative Analysis of Acamprosate and Disulfiram in Treating Alcohol Use Disorder

Acamprosate and Disulfiram are both approved by the FDA for the treatment of Alcohol Use Disorder (AUD), but they work in different ways and have distinct side effects. A study on their combined efficacy suggests that while each has its benefits, the effectiveness of these medications may be enhanced when used together. Acamprosate is typically taken as a 333 mg oral tablet three times a day, whereas Disulfiram is administered once daily at doses ranging from 250 mg to 500 mg.

Acamprosate may be slightly more effective in promoting abstinence, while Disulfiram is a second-line option and is most effective under supervised treatment settings. Disulfiram works by producing an adverse reaction to alcohol intake, which is beneficial for individuals who are motivated to quit and can adhere to strict avoidance of alcohol. Acamprosate, on the other hand, is thought to stabilize chemical signaling in the brain that would otherwise be disrupted by alcohol withdrawal.

Side effects of these medications vary, with Acamprosate generally being well-tolerated, and Disulfiram causing more significant reactions when alcohol is consumed. The choice between Acamprosate and Disulfiram may be influenced by an individual’s specific circumstances, including their motivation to abstain, the need for supervised treatment, and their ability to tolerate side effects.

Both medications have shown efficacy in clinical trials, but not all studies agree on the level of their effectiveness. Therefore, the decision to use Acamprosate or Disulfiram should be made in consultation with a healthcare provider, considering the patient’s unique needs and treatment goals.

For more detailed information on these medications, readers can refer to systematic reviews and meta-analyses available on PubMed and other peer-reviewed sources.

Patient Experiences with Acamprosate for Alcohol Use Disorder

Individuals with Alcohol Use Disorder (AUD) often face significant challenges in their journey towards recovery. Acamprosate, a medication approved by the U.S. Food and Drug Administration, has been recognized as an effective adjunct to psychosocial interventions for these individuals. With over 25 placebo-controlled, double-blind trials backing its efficacy, Acamprosate has been generally found to reduce the risk of returning to drinking and to increase the cumulative duration of abstinence in patients with alcohol dependence.

Patient experiences with Acamprosate are diverse, reflecting the complexity of AUD treatment. While clinical trials have shown its effectiveness in reducing cravings and promoting abstinence following detoxification, individual responses can vary. Patients have noted that Acamprosate can serve as a valuable tool in managing symptoms and improving overall health and functioning. Its tolerability, with a low propensity for drug interactions and the ability to use without dosage adjustment in patients with mild to moderate hepatic impairment, further underscores its practicality in treatment regimens.

However, it is crucial to acknowledge that the success of Acamprosate is often closely tied to concurrent psychosocial support. Therapies such as cognitive behavioral therapy, motivational enhancement therapy, and participation in 12-step programs are frequently mentioned by patients as critical components of a comprehensive treatment plan that includes Acamprosate. The medication’s role in modulating glutamate neurotransmission, which is believed to be a factor in alcohol withdrawal, adds a neurochemical dimension to the holistic approach of AUD treatment that many patients find beneficial.

Despite these positive aspects, it is important for patients and healthcare providers to consider potential side effects and the necessity of dosage adjustments or contraindications for patients with renal impairment. Patient narratives highlight the importance of personalized care and the need for ongoing monitoring and adjustment in treatment plans.

Exploring the Horizon: Future Research in Acamprosate for Alcohol Use Disorder

Recent studies have set the stage for the future of Acamprosate in the treatment of Alcohol Use Disorder (AUD), marking it as an area of active investigation. With Acamprosate already demonstrating efficacy in multiple placebo-controlled trials, researchers are now focusing on understanding its mechanisms of action and identifying patient profiles that may predict better treatment outcomes. Pilot studies are exploring the augmentation of Acamprosate with other medications, like escitalopram, to treat concurrent major depressive disorder and AUD.

Genetic research is also underway, aiming to unveil the metabolomic profiles associated with differential treatment responses. This could lead to personalized therapy approaches, enhancing the efficacy of Acamprosate for individual patients. Investigations into the molecular and cellular effects of Acamprosate suggest that the modulation of hyper-glutamatergic states and the involvement of various glutamate receptors are key to its function in relapse prevention.

Future research directions include the assessment of calcium levels in the plasma or brain as potential mediators of Acamprosate’s anti-relapse efficacy, as well as the development of more sophisticated animal models to better understand its pharmacological profile. Furthermore, preclinical research is expected to bridge the gap between laboratory findings and clinical application, potentially leading to the discovery of new pharmacotherapeutics for AUD. As the body of evidence grows, the prospects for Acamprosate in AUD treatment continue to evolve, underscoring the importance of ongoing research for improving patient outcomes.

Alcohol addiction can be difficult and potentially dangerous to recover from on your own. Severe alcohol withdrawal can be deadly, so heavy alcohol users should not attempt to wean off alcohol without the help of a professional medical detox facility. Alcohol addiction treatment will begin with a detox period that focuses on managing any uncomfortable or severe withdrawal symptoms that arise. After detox ends, patients begin a rehab program that teaches them how to cope without alcohol and maintain sobriety.

Detox and rehab can take place in inpatient or outpatient settings. Outpatient treatment is best for mild alcohol addictions, and it allows patients to attend doctor and therapy visits while still living at home. Inpatient treatment is best for moderate to severe alcohol addictions or people who have relapsed. Inpatient treatment involves living on-site at the detox or rehab facility, an approach that keeps patients in a healing environment and allows for better monitoring and treatment.

The Recovery Village Cherry Hill at Cooper provides a full continuum of care, from medical detox and inpatient rehab to aftercare. We are here to help you and those you love recover from addiction and begin a healthier, alcohol-free future. Contact us to learn more about alcohol addiction treatment programs that can work well for your needs in recovery.


Medical Disclaimer: The Recovery Village aims to improve the quality of life for people struggling with a substance use or mental health disorder with fact-based content about the nature of behavioral health conditions, treatment options and their related outcomes. We publish material that is researched, cited, edited and reviewed by licensed medical professionals. The information we provide is not intended to be a substitute for professional medical advice, diagnosis or treatment. It should not be used in place of the advice of your physician or other qualified healthcare provider.

Get your life back

Recovery is possible. Begin your journey today

Call Us Now Admissions Check Insurance

What To Expect

When you call our team, you will speak to a Recovery Advocate who will answer any questions and perform a pre-assessment to determine your eligibility for treatment. If eligible, we will create a treatment plan tailored to your specific needs. If The Recovery Village is not the right fit for you or your loved one, we will help refer you to a facility that is. All calls are 100% free and confidential.

All calls are 100% free and confidential.